Disease Progression Staging Synthesis

Disease Progression Staging Synthesis

Overview

Neurodegenerative diseases progress through defined stages of biological and clinical change, from the earliest detectable biomarker alterations through to end-stage neurodegeneration. Each disease has its own staging framework, rooted in distinct neuropathology — amyloid-beta/tau for Alzheimer's Disease, alpha-synuclein for Parkinson's Disease, TDP-43 for ALS and FTD. Yet there are remarkable commonalities: all begin with a prodromal phase of biomarker abnormalities preceding clinical symptoms, progress through characteristic neuroanatomical sequences, and culminate in widespread neuronal loss. Understanding these staging mechanisms is essential for early diagnosis, clinical trial design, and therapeutic intervention timing.

This synthesis maps disease progression frameworks across the major neurodegenerative diseases, compares staging architectures, identifies cross-disease patterns, and highlights the therapeutic implications of staging-based intervention windows.

Alzheimer's Disease Staging

NIA-AA AT(N) Research Framework

The 2018 NIA-AA Research Framework[@jack2018niaaa] defines Alzheimer's disease by biomarker profiles rather than clinical syndrome, enabling biological staging independent of symptom onset. The AT(N) classification categorizes biomarkers into three pathologic domains:

• A (Amyloid): CSF Aβ42, Aβ42/40 ratio, PET amyloid imaging
• T (Tau): CSF p-tau181, p-tau217, tau PET
• (N) (Neurodegeneration): CSF t-tau, FDG-PET hypometabolism, MRI atrophy

Disease Progression Staging Synthesis

Overview

Neurodegenerative diseases progress through defined stages of biological and clinical change, from the earliest detectable biomarker alterations through to end-stage neurodegeneration. Each disease has its own staging framework, rooted in distinct neuropathology — amyloid-beta/tau for Alzheimer's Disease, alpha-synuclein for Parkinson's Disease, TDP-43 for ALS and FTD. Yet there are remarkable commonalities: all begin with a prodromal phase of biomarker abnormalities preceding clinical symptoms, progress through characteristic neuroanatomical sequences, and culminate in widespread neuronal loss. Understanding these staging mechanisms is essential for early diagnosis, clinical trial design, and therapeutic intervention timing.

This synthesis maps disease progression frameworks across the major neurodegenerative diseases, compares staging architectures, identifies cross-disease patterns, and highlights the therapeutic implications of staging-based intervention windows.

Alzheimer's Disease Staging

NIA-AA AT(N) Research Framework

The 2018 NIA-AA Research Framework[@jack2018niaaa] defines Alzheimer's disease by biomarker profiles rather than clinical syndrome, enabling biological staging independent of symptom onset. The AT(N) classification categorizes biomarkers into three pathologic domains:

• A (Amyloid): CSF Aβ42, Aβ42/40 ratio, PET amyloid imaging
• T (Tau): CSF p-tau181, p-tau217, tau PET
• (N) (Neurodegeneration): CSF t-tau, FDG-PET hypometabolism, MRI atrophy

The preclinical AD phase (A+T−(N)− and A+T+(N)−) can persist for 15–20 years before symptom onset[@villain2012displaying]. Tau PET studies show that tauopathy spreads in a predictable spatial pattern: from entorhinal cortex → hippocampus → limbic regions → isocortical association areas[@schwarz2016comparing].

Clinical Dementia Staging

For patients with symptoms, the Clinical Dementia Rating (CDR) scale provides a 0–3 staging of dementia severity:

• CDR 0: Normal cognition
• CDR 0.5: Mild cognitive impairment (questionable impairment)
• CDR 1: Mild dementia (impairment in 1+ domains, preserved independence)
• CDR 2: Moderate dementia (significant impairment, requiring some assistance)
• CDR 3: Severe dementia (severe cognitive decline, total dependence)

Thal Amyloid Phases

The [Thal amyloid staging](/mechanisms/amyloid-beta-deposition-staging) system[@thal2005phases] defines five sequential phases of amyloid plaque deposition observable at autopsy:

Amyloid-Tau-Neurodegeneration Timeline

Biomarker studies establish a characteristic temporal ordering[@villain2012displaying][@blennow2005gamma]:

Parkinson's Disease Staging

Braak Staging of Alpha-Synuclein Pathology

The [Braak staging](/mechanisms/alpha-synuclein-prion-like-spreading) system[@braak2003staging][@braak2004neuroanatomy] describes the stereotypic propagation of alpha-synuclein (a-syn) pathology through the nervous system:

| Stage | Primary Sites | Clinical Correlation |
|-------|--------------|---------------------|
| Stage 1 | Olfactory bulb, enteric nervous system | Preclinical, anosmia possible |
| Stage 2 | Lower brainstem (dorsal motor nucleus, raphe nuclei, coeruleus) | Prodromal PD, RBD onset |
| Stage 3 | Upper brainstem (substantia nigra pars compacta) | Motor symptoms emerge (PD diagnosis) |
| Stage 4 | Limbic system (amygdala, hippocampus) | Cognitive changes appear |
| Stage 5 | Neocortex (associative areas) | Dementia, hallucinations |
| Stage 6 | Primary sensory/motor cortex | Advanced PD, severe cognitive decline |

This staging suggests that PD begins in the periphery (olfactory and enteric nervous system) and spreads centripetally to the CNS. The [gut-first hypothesis](/mechanisms/gut-first-brains-first-pd-hypothesis) posits that alpha-synuclein pathology initiates in the enteric nervous system, propagating via the vagus nerve to the dorsal motor nucleus[@sanchez2018gut].

MDS Clinical Staging

The Movement Disorder Society (MDS) Clinical Staging of PD[@goetz2008movement]:

• Stage 1: Unilateral involvement only
• Stage 2: Bilateral involvement without postural impairment
• Stage 3: Mild bilateral disease with postural instability (functionally independent)
• Stage 4: Severe disability but still able to walk/stand without assistance
• Stage 5: Wheelchair-bound or bedridden unless aided

Prodromal PD

The [prodromal phase of PD](/mechanisms/pd-prodromal-phase-biomarkers) encompasses a decade or more before motor diagnosis[@siderowf2018clinical]:

• REM sleep behavior disorder (RBD) — 50–80% of RBD patients develop synucleinopathy within 10–14 years
• Olfactory dysfunction — anosmia precedes motor symptoms by years
• Constipation — may precede motor diagnosis by decades
• Depression — non-motor symptom emerging in prodromal phase

Amyotrophic Lateral Sclerosis (ALS) Staging

King's Clinical Staging

ALS progresses through a clinically-defined staging system[@balendra2024staging]:

| Stage | Criteria | Functional Status |
|-------|---------|-------------------|
| Stage 1 | Diagnosis | Functional independence, 1-2 regions affected |
| Stage 2 | 3 body regions OR first nutritional/respiratory failure | Multiplying regions, beginning support needs |
| Stage 3 | Second intervention required | Wheelchair-dependent,PEG/RIP needs |
| Stage 4 | One intervention fulfilled | Advanced disease, comprehensive care |
| Stage 5 | Both interventions fulfilled | End-stage, hospice/palliative |

The King's staging is based on the [El Escorial](/mechanisms/als-diagnostic-criteria-revised) criteria regions (bulbar, cervical, thoracic, lumbar) and the need for nutritional (PEG) or respiratory (non-invasive ventilation) support.

Milano-Torino (MITOS) Staging

MITOS is a simpler 0-4 staging based on functional progression[@chio2009validation]:

• Stage 0: Pre-symptomatic
• Stage 1: Symptom onset, diagnosis
• Stage 2: Involvement of second region
• Stage 3: PEG or NIV initiation
• Stage 4: Death

Disease Progression Rate Biomarkers

Key biomarkers for ALS staging and progression tracking:

• Neurofilament light chain (NfL) in CSF and blood — elevated from preclinical phase, correlates with disease aggressiveness[@benatar2023neurofilament]
• Creatine kinase (CK) — elevated in 50% of ALS patients
• EMG/NCS — detects subclinical denervation
• Respiratory function (FVC, SNIP) — quarterly monitoring required
• [C9orf72](/mechanisms/c9orf72-hexanucleotide-repeat-als-ftd-causal-chain) hexanucleotide expansion carriers show slower progression but earlier onset

Frontotemporal Dementia (FTD) Staging

FTLD Staging Architecture

FTD encompasses multiple clinical variants and underlying pathologies, complicating unified staging[@rack:FTDstaging]:

• Behavioral variant FTD (bvFTD): Progresses from early behavioral disinhibition/apathy to global cognitive decline
• Primary progressive aphasia (PPA): Language variants (nfvPPA, svPPA, lvPPA) with selective progressive deterioration
• [C9orf72](/mechanisms/c9orf72-hexanucleotide-repeat-als-ftd-causal-chain) expansion → TDP-43 type B pathology
• [MAPT](/mechanisms/mapt-tau-aggregation-psp-causal-chain) mutations → tau pathology (3R/4R)
• [GRN](/mechanisms/grn-progranulin-ftd-causal-chain) mutations → TDP-43 type A pathology

Cross-Disease FTD-ALS Spectrum

The [FTD-ALS spectrum](/mechanisms/ftd-als-spectrum-disorders) represents a continuum[@lillo2018overlap]:

• ~15% of ALS patients develop FTD features
• ~15% of FTD patients develop motor neuron features
• [C9orf72](/mechanisms/c9orf72-hexanucleotide-repeat-als-ftd-causal-chain) hexanucleotide repeat expansion is the major shared genetic cause

Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS)

NINDS PSP Staging

The [NINDS PSP criteria](/mechanisms/progressive-supranuclear-palsy-diagnostic-criteria) define phenotypic variants and disease progression[@hoglinger2017clinical]:

| Stage | Dominant Features | Progression Pattern |
|-------|------------------|---------------------|
| PSP-P | Richardson's syndrome: vertical gaze palsy, early falls | Cortical-subcortical involvement |
| PSP-PAGF | Pure akinesia with gait freezing | Isolated motor dysfunction |
| PSP-PGF | Progressive gait freezing | Frontal executive preserved longer |
| PSP-CBS | Corticobasal syndrome features | Asymmetric cortical involvement |

CBS Progression

[Corticobasal syndrome](/mechanisms/corticobasal-syndrome-diagnostic-criteria) is clinically heterogeneous, with progression varying by underlying pathology (CBD pathology vs. AD pathology vs. PSP pathology):

• Asymmetric cortical signs (apraxia, alien limb) → bilateral involvement
• Frontal-executive decline → global dementia
• Parkinsonism → less responsive to levodopa over time

Cross-Disease Staging Comparison

Unified Themes Across Diseases

Despite distinct pathologies, all major neurodegenerative diseases share staging principles:

| Principle | AD | PD | ALS | FTD | PSP |
|-----------|----|----|-----|-----|-----|
| Biomarker prodromal phase | 15-20 years | 5-10 years | 1-2 years | 5-15 years | 2-5 years |
| Neuroanatomical sequence | EC → HC → Limbic → Cortex | ENS → Brainstem → SN → Limbic → Cortex | Lower motor → Upper motor → Bulbar → Cognitive | Frontal/Temporal → Widespread | Subcortical → Cortical |
| Clinical threshold | CDR 0.5 | MDS Stage 1 | King's Stage 1 | Clinical diagnosis | NINDS Stage 1 |
| Primary pathology | Aβ plaques + tau NFTs | α-Syn inclusions | TDP-43 inclusions | TDP-43 or tau | 4R tau |
| Propagation mechanism | Templated misfolding, prion-like | Prion-like, transsynaptic | Prion-like, motor neuron-to-neuron | Prion-like, transsynaptic | Unknown templating |

Disease Duration Comparison

| Disease | Typical Duration | Prodromal to Diagnosis | Diagnosis to Death |
|---------|----------------|----------------------|-------------------|
| AD | 8-15 years | 15-20 years | 8-12 years |
| PD | 15-25 years | 5-10 years | 10-15 years |
| ALS | 2-5 years | 1-2 years | 2-5 years |
| FTD | 6-12 years | 5-15 years | 3-10 years |
| PSP | 5-9 years | 2-5 years | 3-7 years |

Staging Biomarker Commonalities

Several biomarker classes serve as cross-disease staging markers:

• Neurofilament light chain (NfL) — elevated in all neurodegenerative diseases, correlates with progression rate and disease stage[@benatar2023neurofilament]
• CSF total tau (t-tau) — elevated in AD, also elevated in other neurodegenerative conditions
• FDG-PET hypometabolism — staging marker in AD (posterior cingulate) and FTD (frontal/temporal)
• MRI atrophy — staging correlates across all diseases

Therapeutic Window and Staging Implications

Window of Opportunity

The staging frameworks reveal critical windows for therapeutic intervention:

| Disease | Optimal Intervention Window | Rationale |
|---------|----------------------------|-----------|
| AD | Preclinical (A+ T−) to early MCI | Prevent tau spread, preserve neuronal networks |
| PD | Prodromal (RBD, anosmia) to Stage 1 | Prevent alpha-synuclein propagation beyond brainstem |
| ALS | At diagnosis (King's Stage 1) | Rapid progression leaves minimal window |
| FTD | Genetic carriers, prodromal | C9orf72, GRN, MAPT carriers identifiable pre-symptomatically |
| PSP | Early (within 2 years of onset) | More responsive to tau-targeting before widespread atrophy |

Trial Design Implications

• Enrichment: Use biomarker staging to enrich trials for patients most likely to benefit
• Primary prevention: A+ individuals without symptoms (AD) or C9orf72+ family members (ALS)
• Secondary prevention: A+T+ cognitively normal (AD), RBD+ prodromal (PD)
• Disease-modifying: Symptomatic patients with early-stage disease
• Symptomatic: Moderate to severe disease where disease-modifying agents may be insufficient

Staging-Adapted Endpoints

| Endpoint Type | Application | Staging Phase |
|--------------|------------|---------------|
| Biomarker (CSF, PET) | Primary endpoint | Preclinical, prodromal |
| CDRSB, MDS-UPDRS | Co-primary with biomarker | Symptomatic |
| ADCS-ADL, ALSFRS-R | Functional endpoints | All stages |
| Survival / time-to-event | Regulatory approval | Advanced disease |

Knowledge Gaps and Research Priorities

Cross-Disease Synthesis

The analysis reveals several unifying principles:

• Neurodegenerative diseases share a canonical staging architecture: Prodromal biomarker phase → clinical threshold → progressive neuroanatomical spread → functional decline → death. The duration of each phase varies, but the sequence is conserved.
• Neurofilament light chain (NfL) emerges as the most cross-disease-validated staging biomarker, elevated in prodromal and symptomatic phases across AD, PD, ALS, FTD, and PSP. Its value lies in tracking disease progression rate rather than diagnosis.
• The "30-year window": AD has the longest documented prodromal phase (15-20 years), while ALS has the shortest (1-2 years). This dramatically affects intervention strategy — AD allows primary prevention, ALS demands immediate aggressive treatment.
• Pathology-agnostic biomarkers (neurodegeneration markers, functional imaging) enable cross-disease staging comparisons that could inform unified therapeutic frameworks.
• Synucleinopathies (PD, DLB, MSA) form a staging continuum, with [dementia with Lewy bodies](/mechanisms/dementia-with-lewy-bodies-pathogenesis) representing PD with early and prominent neocortical involvement (Braak Stage 5-6).

Cross-Links to Existing Wiki Pages

• [Amyloid-beta deposition staging](/mechanisms/amyloid-beta-deposition-staging)
• [Alpha-synuclein prion-like spreading](/mechanisms/alpha-synuclein-prion-like-spreading)
• [Parkinson's prodromal phase biomarkers](/mechanisms/pd-prodromal-phase-biomarkers)
• [ALS diagnostic criteria revised](/mechanisms/als-diagnostic-criteria-revised)
• [C9orf72 hexanucleotide repeat ALS-FTD causal chain](/mechanisms/c9orf72-hexanucleotide-repeat-als-ftd-causal-chain)
• [Progressive supranuclear palsy diagnostic criteria](/mechanisms/progressive-supranuclear-palsy-diagnostic-criteria)
• [Corticobasal syndrome diagnostic criteria](/mechanisms/corticobasal-syndrome-diagnostic-criteria)
• [Gut-first vs brain-first PD hypothesis](/mechanisms/gut-first-brains-first-pd-hypothesis)
• [Neurofilament light chain biomarker](/mechanisms/neurofilament-light-chain-nfl-biomarker)
• [Therapeutic synergy and combination approach rankings](/mechanisms/therapeutic-synergy-combination-rankings)
• [Hallmarks of aging in neurodegeneration](/mechanisms/hallmarks-of-aging-neurodegeneration-synthesis)
• [Biomarker-therapeutic development nexus](/mechanisms/biomarker-therapeutic-development-nexus)

References